We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cesca Therapeutics Inc | NASDAQ:KOOL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.14 | 3.30 | 5.22 | 0 | 00:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) : July 23 , 2019
CESCA THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
333-82900 |
|
94-3018487 |
||
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
||
of Incorporation) |
|
File Number) |
|
Identification No.) |
||
|
|
|
||||
2711 Citrus Road, Rancho Cordova, California |
|
95742 |
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code (949) 753-0624
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 16(b) of the Exchange Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $.001 par value |
KOOL |
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01. |
Entry into a Material Definitive Agreement. |
On July 23, 2019, Cesca Therapeutics Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to the Convertible Note Agreement (the “Agreement”) dated January 29, 2019 by the Company and Orbrex USA Co. Limited. Under the terms of the Amendment, the Maturity Date of Note was extended from July 29, 2020 to July 31, 2022. All other terms of the Agreement remained the same.
The foregoing descriptions of the Amendment does not purport to be complete and are qualified in their entirety by reference to the full text of the Amendment, which is attached as Exhibits 10.1 hereto and incorporated herein by reference.
Item 9.01. |
Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CESCA THERAPEUTICS INC . |
|
(Registrant) |
|
Dated: July 29, 2019 |
/s/ Jeff Cauble |
Jeff Cauble, Principal Financial and Accounting Officer |
1 Year Cesca Therapeutics Chart |
1 Month Cesca Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions